HIV-Associated Histoplasmosis: Current Perspectives
| Autor: | Evelyn Villacorta Cari, Nicole Leedy, L. Joseph Wheat, Thein Myint |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cellular immunity
Epidemiology Itraconazole Dermatology 030312 virology Histoplasmosis 03 medical and health sciences 0302 clinical medicine Immune reconstitution inflammatory syndrome Antigen Virology Histoplasma medicine 030212 general & internal medicine 0303 health sciences biology business.industry Health Policy biology.organism_classification medicine.disease Complement fixation test Infectious Diseases Immunology business Viral load medicine.drug |
| Zdroj: | HIV/AIDS - Research and Palliative Care. 12:113-125 |
| ISSN: | 1179-1373 |
| DOI: | 10.2147/hiv.s185631 |
| Popis: | Histoplasmosis is an endemic mycosis caused by Histoplasma capsulatum. Infection develops by inhalation of microconidia from environmental sites inhabited by birds and bats. Disseminated disease is the usual presentation due to impaired cellular immunity. Common clinical manifestations include fever, fatigue, malaise, anorexia, weight loss, and respiratory symptoms. Histoplasma antigen detection is the most sensitive method for diagnosis. The sensitivity of the MVista® Quantitative Histoplasma antigen enzyme immunoassay is 95-100% in urine, over 90% in serum and bronchoalveolar lavage (BAL) antigen and 78% in cerebral spinal fluid (CSF). A proven diagnosis can be established by culture or pathology with sensitivities between 70% and 80%. The sensitivity of antibody detection by immunodiffusion or complement fixation was between 60% and 70%. Diagnosis using molecular methods has not been adequately validated for implementation and FDA cleared assays are unavailable. Liposomal amphotericin B should be used for 1-2 weeks followed by itraconazole for at least one year until CD4 counts are above 150 cells/mm3, HIV viral load is below 400 copies/mL and Histoplasma urine antigen is negative. Serum itraconazole level should be monitored to avoid drug toxicity. Antigen should be measured periodically to establish that treatment is effective and to assist in identifying relapse. The incidence of immune reconstitution inflammatory syndrome is low but it must be considered in patients who are thought to be failing antifungal treatment as it does not respond to changing antifungal agents but rather to initiation of corticosteroid therapy. In this review, we discuss pathogenesis, clinical manifestations, diagnosis and treatment based on personal experience and relevant publications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|